OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Tarantino on Patient Awareness of the Platinum Shortage in Breast Cancer

August 18th 2023

Paolo Tarantino, MD, discusses typical conversations oncologists should have with patients regarding the platinum chemotherapy shortage, as well as the importance of honest communication about treatment regimen changes.

Dr Fonkoua on the Effects of the Platinum Chemotherapy Shortage on Disparities in Cancer Care

August 18th 2023

Lionel A. Kankeu Fonkoua, MD, discusses how the platinum chemotherapy shortage in the United States may exacerbate disparities in cancer care and the importance of conducting research to investigate the potential implications of this shortage on patients in underserved communities.

Dr Islam on the Current and Expanding Role of Pirtobrutinib in MCL

August 18th 2023

Prioty Islam, MD, MSc, discusses how the FDA approval of the noncovalent BTK inhibitor pirtobrutinib has transformed the treatment of patients with mantle cell lymphoma, and where this agent fits in to the current treatment armamentarium.

Dr Grivas on Addressing Unmet Needs in Urothelial Cancer

August 18th 2023

Petros Grivas, MD, PhD, discusses several unmet needs within urothelial cancer, as well as how to potentially ameliorate them.

Dr Yentz on Treatment Decisions for Patients With Kidney Cancer

August 17th 2023

Sarah Elizabeth Yentz, MD, discusses how she decides between an immunotherapy agent plus a TKI combination vs 2-agent immunotherapy for patients with renal cell carcinoma.

Dr Reichert on Novel Agents and Pathways Being Explored in Prostate Cancer

August 17th 2023

Zachery Roger Reichert, MD, PhD, discusses novel agents and pathways under exploration in prostate cancer.

Dr Mascarenhas on the Rationale for the KRT-232-109 Study in Secondary Myelofibrosis

August 17th 2023

John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.

Megahed on the Effects of NGS on First-Line Treatment Decisions in NSCLC

August 17th 2023

Ahmed Megahed, MBBCh, discusses the rationale for investigating the effects of next-generation sequencing on first-line treatment decisions for patients with stage IV non–small cell lung cancer.

Dr Van Tine on the SPEARHEAD-1 Trial of Afami-Cel in Advanced Synovial Sarcoma

August 17th 2023

Brian A. Van Tine, MD, PhD, discusses findings from the overall survival analysis of the phase 2 SPEARHEAD-1 trial in patients with advanced synovial sarcoma.

Dr. Mehmi on Fianlimab and Cemiplimab in Patients with Poor-Risk, Advanced Melanoma

August 17th 2023

Inderjit Mehmi, MD, discusses results from a subgroup analysis of patients with advanced melanoma and poor-risk features given fianlimab and cemiplimab in a phase 1 trial.

Dr Santos on the ADAURA Trial of Adjuvant Osimertinib in EGFR-Mutant NSCLC

August 17th 2023

Edgardo S. Santos, MD, FACP, discusses key survival data from the pivotal phase 3 ADAURA trial in early-stage non–small cell lung cancer.

Dr Kopetz on the Investigation of Encorafenib, Cetuximab, and Chemotherapy in mCRC

August 16th 2023

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BREAKWATER trial in patients with BRAF V600E–mutant metastatic colorectal cancer.

Dr Williams on the Importance of Investigating ADCs in Ovarian Cancer

August 16th 2023

Heather R. Williams, MD, discusses the importance of further exploring the use of antibody drug conjugates in ovarian cancer, specifically highlighting the investigation of mirvetuximab soravtansine in this population.

Dr Schinke on the Rationale for the MonumenTAL-1 Trial in Multiple Myeloma

August 16th 2023

Carolina D. Schinke, MD, discusses the rationale for conducting the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Dr Massarelli on Addressing Unmet Needs in SCLC

August 16th 2023

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in the treatment of patients with small cell lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as how further research may help mitigate these needs.

Franklin on Strategies to Ameliorate the Effect of Social Determinants on CRC Screening Rates

August 16th 2023

Isabelle Franklin, discusses strategies healthcare providers can implement to address or ameliorate disparities in place that are affecting screening rates in colorectal cancer.

Dr Dholaria on Ongoing Investigations of Talquetamab and Daratumumab in R/R Multiple Myeloma

August 16th 2023

Bhagirathbhai Dholaria, MBBS, discusses next steps for investigating subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma based on data from the phase 1 TRIMM-2 trial.

Dr Patel on Maintaining Quality of Life While Treating Patients With Multiple Myeloma

August 15th 2023

Krina K. Patel, MD, MSc, discusses maintaining quality of life while treating patients with multiple myeloma, as well as highlights from the phase 3 KarMMa-3 trial.

Dr Masarova on the Investigation of Ropeginterferon Alfa in Essential Thrombocythemia

August 15th 2023

Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.

Franklin on Future Steps for Investigating the Association Between Social Needs and CRC Screening Rates

August 15th 2023

Isabelle Franklin, discusses future steps to be taken following an investigation into the association between self-reported social needs and colorectal cancer screening rates.